Minnetronix said today that it’s adding “Medical” to its name, unveiling a new corporate look to emphasize its focus on the neurocritical care market.
Founded in 1996, the St. Paul, Minn.-based company said it’s developing a line of devices for the neurological ICU, beginning with the Neurapheresis device for treating post-aneurysmal subarachnoid hemorrhage. A first-in-human study is already complete, with an “extended study” planned for this fall, Minnetronix Medical said.
“Minnetronix is growing and broadening its footprint in the healthcare industry. Our new brand better reflects the company we are today and how we are furthering our mission to improve life for patients,” CEO Rich Nazarian said in prepared remarks. “Over more than two decades we’ve gained a breadth and depth of skill and experience that we’re continuing to use to deliver meaningful solutions to our medical device customers as well as neurocritical care physicians and patients.”
The company said it’s continuing to invest in the RF energy, fluid & gas management, optical systems and stimulation & active wearables markets. The Neurapheresis device is designed to remove blood from cerebro-spinal fluid, Minnetronix Medical said.
